{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=23", "query": { "intervention": "antibody-drug conjugate", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 503, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T16:39:19.281Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07063212", "title": "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Sinus Cancer", "Nasal Cavity Cancer", "Oral Cavity Cancer", "Oropharynx Cancer", "Hypopharynx Cancer", "Larynx Cancer", "Oral Squamous Cell Carcinoma", "Oropharynx Squamous Cell Carcinoma", "Hypopharynx Squamous Cell Carcinoma", "Larynx Squamous Cell Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-07-02", "completion_date": "2028-01-02", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07063212" }, { "nct_id": "NCT02227199", "title": "Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-10-10", "completion_date": "2025-07-28", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02227199" }, { "nct_id": "NCT02706899", "title": "Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "vadastuximab talirine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Placebo (for 33A)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-02", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 34, "location_summary": "Gilbert, Arizona • Los Angeles, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706899" }, { "nct_id": "NCT02529553", "title": "A Study of LY3076226 in Participants With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "LY3076226", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-09", "completion_date": "2018-03-28", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania • Charleston, South Carolina • San Antonio, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02529553" }, { "nct_id": "NCT06244485", "title": "A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Valemetostat tosylate", "type": "DRUG" }, { "name": "T-DXd", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-02-22", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 17, "location_summary": "Irvine, California • San Diego, California • Plantation, Florida + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244485" }, { "nct_id": "NCT05872295", "title": "IKS014 in Advanced Solid Tumors That Express HER2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer" ], "interventions": [ { "name": "IKS014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Iksuda Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2023-09-14", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 4, "location_summary": "Newport Beach, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05872295" }, { "nct_id": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Sofetabart Mipitecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "MIRV", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1630, "start_date": "2025-10-22", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213804" }, { "nct_id": "NCT06065371", "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Sacituzumab govetican", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-11-20", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065371" }, { "nct_id": "NCT01026415", "title": "Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinomas", "Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin", "Neoplasms" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rifampin", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "ketoconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2009-12", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2014-12-18", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 6, "location_summary": "Duarte, California • Denver, Colorado • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026415" }, { "nct_id": "NCT05870748", "title": "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ovarian Cancer", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Platinum-resistant Ovarian Cancer" ], "interventions": [ { "name": "Luveltamab tazevibulin", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 600, "start_date": "2023-07-12", "completion_date": "2025-08-26", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-11-09T16:39:19.281Z", "location_count": 37, "location_summary": "Tucson, Arizona • Daly City, California • San Diego, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Daly City", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05870748" } ] }